The Monarch Etrial:improving the clinical outcome in HR^(+)/HER2^(−)early breast cancer:recent results and next steps  

作　　者：François Bertucci Pascal Finetti Emilie Mamessier Alexandre De Nonneville 

机构地区：[1]Laboratory of Predictive Oncology,Cancer Research Center of Marseille,Paoli-Calmettes Institute,Aix-Marseille University,INSERM UMR1068,CNRS UMR725,Team Labelled“Ligue contre le cancer”,Marseille,France [2]Department of Medical Oncology,Paoli-Calmettes Institute,Marseille,France

出　　处：《Cancer Communications》2023年第8期938-942,共5页癌症通讯（英文）

基　　金：Ligue Nationale Contre Le Cancer,Grant/Award Number:EL2022/FB;Association Ruban Rose(Prix Ruban Rose 2020,FB)。

摘　　要：Breast cancer(BC)is the most frequent cancer in women worldwide,and hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR^(+)/HER2^(−))is the most frequent BC subtype.The adjuvant systemic treatment of HR^(+)/HER2^(−)early-stage BC(eBC),based on prognostic factors[1],sometimes includes chemotherapy,and in most cases,it includes endocrine therapy(ET).In the past decade,advancements in ET,such as successive approvals of tamoxifen and aromatase inhibitors and the extension of ET duration to 10 years in high-risk patients.

关 键 词：HER2 cancer CHEMOTHERAPY 

分 类 号：R737.9[医药卫生—肿瘤]